Reminder: Spherix to Hold Business Update Conference Call April 11 at 1:00 p.m. Eastern Time
BETHESDA, Md., April 10, 2012 /PRNewswire/ -- Spherix Incorporated (SPEX) an innovator in biotechnology for therapy in diabetes, metabolic syndrome and atherosclerosis, and providers of technical and regulatory consulting services to food, supplement, biotechnology and pharmaceutical companies would like to remind investors and analysts that the management will host a conference call to provide a business update and answer questions tomorrow, April 11, 2012 beginning at 1:00 p.m. Eastern time. During the call management will review the Company's 2011 financial results, and provide an update on its development progress, including work with SPX-106T.
Last year Spherix undertook an asset-centric growth strategy based on SPX-106T, and is now launching a combination-drug discovery platform based on a dynamic data-driven application simulation (DDDAS) approach. In addition to its own combination drugs, Spherix is looking at Phase 1 and Phase 2 assets to roll-up in this platform. The DDDAS program began at the National Science Foundation and is now being employed to model complex metabolic disease pathways, test potential binary therapies in simulations of various combinations and choose the most effective pair-wise combinations. DDDAS is being deployed in animal and human studies planned by Spherix.
To access the conference call, from the U.S. please dial (866) 322-1352 and from outside the U.S. please dial (706) 643-6246. All listeners should provide the following passcode: 62805777. Individuals interested in listening to the live conference call via the Internet may do so by logging on to the Company's website, www.spherix.com.
Following the end of the conference call, a telephone replay will be available through April 17, 2012, and can be accessed by dialing (855) 859-2056 from the U.S. or (404) 537-3406 from outside of the U.S. All listeners should provide the following passcode: 62805777. The webcast will be available for 30 days.
Spherix Incorporated was launched in 1967 as a scientific research company under the name Biospherics Research. The Company now leverages its scientific and technical expertise and experience through its two subsidiaries Biospherics Incorporated and Spherix Consulting, Inc. Biospherics is dedicated to developing and licensing/marketing proprietary therapeutic products for treatment of diabetes, metabolic syndrome and atherosclerosis. Biospherics is exploring new drugs and combinations for treatment of high triglycerides, a risk factor for atherosclerosis, myocardial infarction, and stroke, and would like a pharmaceutical partner to continue development of D-tagatose as a treatment for diabetes. Spherix's Consulting subsidiary provides scientific and strategic support for suppliers, manufacturers, distributors and retailers of conventional foods, biotechnology-derived foods, medical foods, infant formulas, food ingredients, dietary supplements, food contact substances, pharmaceuticals, medical devices, consumer products and industrial chemicals and pesticides. For more information, please visit www.spherix.com.
This release contains forward-looking statements which are made pursuant to provisions of Section 21E of the Securities Exchange Act of 1934. Investors are cautioned that such statements in this release, including statements relating to planned clinical study design, regulatory and business strategies, plans and objectives of management and growth opportunities for existing or proposed products, constitute forward-looking statements which involve risks and uncertainties that could cause actual results to differ materially from those anticipated by the forward-looking statements. The risks and uncertainties include, without limitation, risks that product candidates may fail in the clinic or may not be successfully marketed or manufactured, we may lack financial resources to complete development of our products, the FDA may interpret the results of studies differently than us, competing products may be more successful, demand for new pharmaceutical products may decrease, the biopharmaceutical industry may experience negative market trends, our continuing efforts to develop products may be unsuccessful, our common stock could be delisted from the Nasdaq Capital Market, and other risks and challenges detailed in our filings with the U.S. Securities and Exchange Commission. Readers are cautioned not to place undue reliance on any forward-looking statements which speak only as of the date of this release. We undertake no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this release or to reflect the occurrence of unanticipated events.
SOURCE Spherix Incorporated